About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Cardiovascular Diseases group is a translational research group within the Cardiology Department of Vall d’Hebron Hospital that performs laboratory, clinical and epidemiological research. In the CIBERCV network we are within the topic of descriptor 2 “Arterial disease, thrombosis and myocardial ischemia-reperfusion injury”. Our contributions in these topics address the following lines:
In the CIBERESP network, our group is interested in the study of effectiveness/cost-effectiveness of cardiovascular interventions, health outcome research and methods in clinical research. The group has 19 principal investigators, 32 active projects and clinical trial and has been done 142 publications in 2020.
PMID: 35053290 Journal: Biomolecules Year: 2022 Reference: Biomolecules. 2022 Jan 16;12(1). pii: biom12010143. doi: 10.3390/biom12010143. Impact factor: 4.879 Publication type: Review in international publication Authors: Llorens-Cebria, Carmen, Molina-Van den Bosch, Mireia, Vergara, Ander, Jacobs-Cacha, Conxita, Soler, Maria Jose et al. DOI: 10.3390/biom12010143
PMID: 35055345 Journal: Journal of Personalized Medicine Year: 2022 Reference: J Pers Med. 2022 Jan 2;12(1). pii: jpm12010030. doi: 10.3390/jpm12010030. Impact factor: 4.945 Publication type: Paper in international publication Authors: Herance, Jose Raul, Simo, Rafael, Velasquez, Mayra Alejandra, Paun, Bruno, Garcia-Leon, Daniel, Aparicio, Carolina, Mares, Roso, Simo-Servat, Olga, Castell-Conesa, Joan, Hernandez, Cristina et al. DOI: 10.3390/jpm12010030
PMID: 35067470 Journal: REVISTA ESPANOLA DE CARDIOLOGIA Year: 2022 Reference: Rev Esp Cardiol (Engl Ed). 2022 Jan 20. pii: S1885-5857(21)00373-X. doi: 10.1016/j.rec.2021.12.001. Impact factor: 4.753 Publication type: Paper in national publication Authors: Ois, Angel, Benito, Begona, Garcia-Elias, Anna, Ble, Mireia, Yanez Bisbe, Laia, Giralt-Steinhauer, Eva, Rodriguez-Campello, Ana, Cladellas Capdevila, Merce, Marti-Almor, Julio, Roquer, Jaume et al. DOI: 10.1016/j.rec.2021.12.001
PMID: 35068655 Journal: REVISTA ESPANOLA DE CARDIOLOGIA Year: 2022 Reference: Rev Esp Cardiol. 2022 Jun;75(6):532-535. doi: 10.1016/j.recesp.2021.11.031. Epub 2022 Jan 17. Impact factor: 4.753 Publication type: Letter whit IF Authors: Gonzalez-Del-Hoyo, Maribel, Servato, Luz, Rodenas, Eduardo, Baneras, Jordi, Ferreira-Gonzalez, Ignacio, Rodriguez-Palomares, Jose et al. DOI: 10.1016/j.recesp.2021.11.031
PMID: 33336506 Journal: CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS Year: 2021 Reference: Catheter Cardiovasc Interv. 2021 Apr 1;97(5):927-937. doi: 10.1002/ccd.29433. Epub 2020 Dec 17. Impact factor: 2.692 Publication type: Paper in international publication Authors: Ruiz-Arroyo, Jose-Ramon, Diez, Jose-Luis, Diarte, Jose-Antonio, Macaya, Fernando, de la Torrre Hernandez, Jose-Maria, Rodriguez-Leor, Oriol, Trillo, Ramiro, Alonso-Briales, Juan, Amat-Santos, Ignacio, Romaguera, Rafael et al. DOI: 10.1002/ccd.29433
PMID: 33253944 Journal: CLINICAL MICROBIOLOGY AND INFECTION Year: 2021 Reference: Clin Microbiol Infect. 2021 Apr;27(4):660-664. doi: 10.1016/j.cmi.2020.11.022. Epub 2020 Nov 28. Impact factor: 8.067 Publication type: Letter whit IF Authors: Baz, Blanca Anaya, Escola-Verge, Laura, Cuervo, Guillermo, de Alarcon, Aristides, Sousa, Dolores, Barca, Laura Varela, Fernandez-Hidalgo, Nuria, de Alarcon, Aristides, Gutierrez-Carretero, Encarnacion, Luque-Marquez, Rafael et al. DOI: 10.1016/j.cmi.2020.11.022
PMID: 33821246 Journal: JACC. Case reports Year: 2021 Reference: JACC Case Rep. 2021 Apr;3(4):566-572. doi: 10.1016/j.jaccas.2021.01.030. Epub 2021 Mar 31. Impact factor: 0 Publication type: Letter or abstract Authors: Burcet, Gemma, Teixido-Tura, Gisela, Calabria, Hug Cuellar, Gonzalez, Ignacio Ferreira, Rodriguez-Palomares, Jose F, Fernandez-Galera, Ruben, Casas, Guillem, Valente, Filipa X, Servato, Maria L, Garcia-Moreno, Laura Gutierrez et al. DOI: 10.1016/j.jaccas.2021.01.030
PMID: 33811970 Journal: MOLECULAR AND CELLULAR ENDOCRINOLOGY Year: 2021 Reference: Mol Cell Endocrinol. 2021 Jun 1;529:111263. doi: 10.1016/j.mce.2021.111263. Epub 2021 Mar 31. Impact factor: 4.102 Publication type: Paper in international publication Authors: Soler, Maria Jose, Seron, Daniel, Garcia-Carro, Clara, Vergara, Ander, Jacobs-Cacha, Conxita, Molina-Van den Bosch, Mireia, Dominguez-Baez, Pamela, Benito, Begona et al. DOI: 10.1016/j.mce.2021.111263
The consensus document is the result of multidisciplinary work that takes into account the risks associated with all stages of women's lives and the differences compared to men.
The study, which involved Vall d'Hebron, developed an action plan to efficiently allocate resources to patients most at risk of suffering this complication.
In light of this evidence, hospitals such as Vall d'Hebron have already started to include warnings about environmental pollution in their hospital discharge plans after a myocardial infarction.
